Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CCR5 [3] Viral protein interaction with cytokine and cytokine receptor, Toxoplasmosis, Viral carcinogenesis D06670 Maraviroc [2] 46, 84
2 CCR5 [3] Viral protein interaction with cytokine and cytokine receptor, Toxoplasmosis, Viral carcinogenesis D09878 Cenicriviroc [1] 94
3 MAPK14 [4] VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D09639 Losmapimod [2] 113, 222
4 MAPK14 [4] VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D10959 Neflamapimod [1] 8
5 ALOX5 [1] Toxoplasmosis D00414 Zileuton [3] 85, 160, 164
6 ALOX5 [1] Toxoplasmosis D01773 Oxatomide [1] 113
7 HLA-DMA [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
8 HLA-DMB [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
9 HLA-DOA [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
10 HLA-DOB [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
11 HLA-DPA1 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
12 HLA-DPB1 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
13 HLA-DQA1 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
14 HLA-DQA2 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
15 HLA-DQB1 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
16 HLA-DRA [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
17 HLA-DRB1 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
18 HLA-DRB3 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
19 HLA-DRB4 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
20 HLA-DRB5 [4] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
21 IFNG [3] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis D04242 Fontolizumab [1] 46
22 IFNG [3] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis D11120 Emapalumab [2] 49, 107
23 IFNGR1 [2] Toxoplasmosis, Tuberculosis D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
24 IFNGR2 [2] Toxoplasmosis, Tuberculosis D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
25 IL10 [4] Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, Toxoplasmosis, Tuberculosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
26 IL12A [3] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
27 IL12B [3] Type I diabetes mellitus, Toxoplasmosis, Tuberculosis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
28 JAK1 [3] Toxoplasmosis, Tuberculosis, Viral carcinogenesis D09959 Ruxolitinib [1] 228
29 JAK1 [3] Toxoplasmosis, Tuberculosis, Viral carcinogenesis D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
30 JAK1 [3] Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10308 Baricitinib [13] 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
31 JAK1 [3] Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10653 Peficitinib [1] 46
32 JAK1 [3] Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10871 Filgotinib [6] 46, 53, 96, 97, 222, 271
33 JAK1 [3] Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10944 Itacitinib [5] 46, 51, 60, 97, 228
34 JAK1 [3] Toxoplasmosis, Tuberculosis, Viral carcinogenesis D10994 Upadacitinib [8] 40, 41, 46, 49, 96, 97, 107, 271
35 JAK2 [2] Toxoplasmosis, Tuberculosis D09959 Ruxolitinib [1] 228
36 JAK2 [2] Toxoplasmosis, Tuberculosis D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
37 JAK2 [2] Toxoplasmosis, Tuberculosis D10308 Baricitinib [13] 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
38 JAK2 [2] Toxoplasmosis, Tuberculosis D10653 Peficitinib [1] 46
39 NFKB1 [5] Yersinia infection, Toxoplasmosis, Tuberculosis, Transcriptional misregulation in cancer, Viral carcinogenesis D01146 Iguratimod [4] 46, 51, 53, 271
40 MAPK11 [4] VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D09639 Losmapimod [2] 113, 222
41 MAPK11 [4] VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D10959 Neflamapimod [1] 8
42 MAPK13 [4] VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D09639 Losmapimod [2] 113, 222
43 MAPK13 [4] VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D10959 Neflamapimod [1] 8
44 BCL2 [2] Toxoplasmosis, Tuberculosis D10679 Venetoclax [1] 28
45 RELA [5] Yersinia infection, Toxoplasmosis, Tuberculosis, Transcriptional misregulation in cancer, Viral carcinogenesis D12181 Edasalonexent [1] 113
46 MAPK12 [4] VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D09639 Losmapimod [2] 113, 222
47 MAPK12 [4] VEGF signaling pathway, Yersinia infection, Toxoplasmosis, Tuberculosis D10959 Neflamapimod [1] 8
48 TGFB1 [2] Toxoplasmosis, Tuberculosis D09620 Fresolimumab [4] 51, 85, 222, 274
49 TGFB2 [2] Toxoplasmosis, Tuberculosis D09620 Fresolimumab [4] 51, 85, 222, 274
50 TGFB3 [2] Toxoplasmosis, Tuberculosis D09620 Fresolimumab [4] 51, 85, 222, 274
51 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D00742 Etanercept [17] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
52 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D00754 Thalidomide [20] 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
53 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
54 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D02597 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
55 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D02598 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
56 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D03441 Certolizumab pegol [8] 37, 46, 49, 96, 97, 107, 226, 271
57 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D04358 Golimumab [8] 46, 56, 84, 96, 97, 107, 270, 271
58 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D04687 Lenalidomide [8] 16, 26, 28, 34, 49, 284, 300, 331
59 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D05393 Pegsunercept [1] 46
60 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
61 TNF [6] Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Toxoplasmosis, Tuberculosis D09944 Ozoralizumab [1] 46
62 TYK2 [1] Toxoplasmosis D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
63 TYK2 [1] Toxoplasmosis D11817 Deucravacitinib [2] 96, 97
64 CASP9 [4] VEGF signaling pathway, Toxoplasmosis, Tuberculosis, Viral myocarditis D11195 Rimiducid [6] 19, 60, 65, 284, 285, 326
65 CD40 [3] Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis D11357 Bleselumab [1] 222
66 CD40 [3] Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis D11597 Ravagalimab [2] 53, 97
67 CD40 [3] Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis D11610 Iscalimab [2] 49, 53
68 CD40LG [2] Toxoplasmosis, Viral myocarditis D06193 Toralizumab [1] 63